InflaRx (NASDAQ:IFRX) Earns "Buy" Rating from HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of InflaRx (NASDAQ:IFRX - Free Report) in a report published on Thursday, Benzinga reports. They currently have a $8.00 target price on the stock.

InflaRx Price Performance

Shares of InflaRx stock remained flat at $1.20 on Thursday. The stock had a trading volume of 306,652 shares, compared to its average volume of 232,244. The stock's fifty day moving average is $1.50 and its 200-day moving average is $1.54. The stock has a market cap of $70.66 million, a PE ratio of -1.40 and a beta of 1.26. InflaRx has a fifty-two week low of $1.14 and a fifty-two week high of $5.20.

InflaRx (NASDAQ:IFRX - Get Free Report) last issued its earnings results on Thursday, March 21st. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). As a group, sell-side analysts predict that InflaRx will post -1 earnings per share for the current fiscal year.

Hedge Funds Weigh In On InflaRx

A number of hedge funds have recently modified their holdings of the business. Franklin Street Advisors Inc. NC increased its position in shares of InflaRx by 49.9% during the fourth quarter. Franklin Street Advisors Inc. NC now owns 75,100 shares of the company's stock valued at $122,000 after acquiring an additional 25,000 shares during the last quarter. Alps Advisors Inc. lifted its stake in InflaRx by 109.4% during the third quarter. Alps Advisors Inc. now owns 83,279 shares of the company's stock worth $248,000 after purchasing an additional 43,501 shares in the last quarter. Raymond James & Associates boosted its position in shares of InflaRx by 7.9% during the fourth quarter. Raymond James & Associates now owns 175,279 shares of the company's stock worth $286,000 after buying an additional 12,873 shares during the period. Raymond James Financial Services Advisors Inc. grew its stake in shares of InflaRx by 18.2% in the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 317,859 shares of the company's stock valued at $518,000 after buying an additional 48,944 shares in the last quarter. Finally, Affinity Asset Advisors LLC raised its holdings in shares of InflaRx by 35.3% in the 3rd quarter. Affinity Asset Advisors LLC now owns 325,097 shares of the company's stock valued at $969,000 after buying an additional 84,897 shares during the period. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.